Sign in with Google
bearish
Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe
543 Views26 Nov 2021 15:30
SUMMARY
- Global Cord Blood (CO US) shares are trading within a range and are expected to have limited upsides due to ongoing merger and policy overhangs.
- The ongoing acquisition proposal from Haitong values the company at a steep discount to the peers and one recently concluded deal in the similar space.
- The company reported muted Q2 results with flat q/q revenue growth and new subscriber adds. Surge in new Covid cases in China may prolong the business recovery.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Foshan Haitian Flavouring & Food (3288 HK): Offering Details & Index Inclusion
- Kioxia IPO Lockup Expiry - US$6.7bn Release, with Shareholders Eager to Sell
- Virgin Australia (VGN AU): Touch & Go for Index Inclusion
- Nikkei 225 Proposal for Dealing With Sony's (6758) Sony Finl Spinoff - A Non-Event but TOPIX Isn't
- Preferred Shares of Five Major Korean Holdcos - Likely to Close the Gap Further With Common Shares
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Global Cord Blood (CO US): Fate Seems to Be Changing as New Growth Engine Added30 Apr 2022
- Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation08 Apr 2022
- Global Cord Blood (CO US): No Immediate Respite Is Seen30 Jan 2022
- Global Cord Blood: Haitong Raids The Bank16 Mar 2021
x